Update: Pharmaron Continuing to Demonstrate Its Leadership in GLP Toxicology Service Capabilities

BEIJING--(BUSINESS WIRE)-- Pharmaron released today an updated summary of its GLP toxicology track record. Pharmaron has operated GLP toxicology facilities in Beijing, China since 2006, and boasts the broadest and most diverse toxicology track record for a CRO with western standards in China. Pharmaron partners are predominantly US biotech and pharmaceutical companies who intend to file IND applications in the US, Europe and Asia.

Pharmaron continues to be the CRO in China that clients trust for their pivotal studies. Pharmaron has received numerous contracts for GLP toxicology services from large international pharmaceutical companies, including some long-term collaborations. The results of a recent FDA inspection attest to the high quality of these services. To date, its partners have submitted over 20 IND packages to the US FDA and other global regulatory authorities, using data produced by Pharmaron.

Pharmaron has performed hundreds of studies to date, including:

  • 13-week studies in rodents, rabbits, canines, non-human primates
  • 6-month studies in rodents and canines
  • 9-month studies in canines
  • 12-month or greater studies in canines and non-human primates
  • Safety Pharmacology (CNS, CV, and Respiratory) studies in rats, canines, and non-human primates

Pharmaron is also highly experienced in non-traditional routes of administration, including continuous infusion dosing in primates for durations of up to 6 months.

The preclinical services team at Pharmaron will continue to explore new technology in the toxicology area, to ensure high quality state-of-the-art services will be provided to the partners.


Tina Huang, +86-10-8072-8800
[email protected]

KEYWORDS:   United States  Asia Pacific  North America  China  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  FDA


Suggested Articles

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.